Dexamethasone

Dexamethasone

SCHEMBL364920

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO.Cl

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR3C1

The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 known ✓ P04150 9/20 0.98
▸ HIF1A Q16665 9/20 0.98
▸ CYP3A4 P08684 7/20 0.98
▸ HSD17B10 Q99714 4/20 0.98
▸ NFKB1 P19838 4/20 0.98
▸ PGR P06401 3/20 0.98
▸ TSHR P16473 2/20 0.98
▸ AR P10275 2/20 0.98
▸ PMP22 Q01453 2/20 0.98
▸ MEN1 O00255 1/20 0.98
▸ CYP2D6 P10635 1/20 0.98
▸ KMT2A Q03164 1/20 0.98
▸ APEX1 P27695 1/20 0.98
▸ NPSR1 Q6W5P4 1/20 0.98
▸ IKBKB O14920 1/20 0.98
▸ CHUK O15111 1/20 0.98
▸ ADRB2 P07550 1/20 0.98
▸ NR3C2 P08235 1/20 0.98
▸ PLA2G2A P14555 1/20 0.98
▸ NFKB2 Q00653 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Betamethasone SCHEMBL14141600 1.00 HIF1A (0.98) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Dexamethasone SCHEMBL4847833 0.99 HIF1A (0.96) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL4847837 0.99 HIF1A (0.96) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL3392690 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL21790369 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL23022353 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL21261932 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL20816248 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL11911310 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1
Betamethasone SCHEMBL12738245 0.99 HIF1A (1.00) HIF1ANR3C1CYP3A4HSD17B10NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210868-A1 Methods of Treatment Using ICAM-Modulating Agents AVM BIOTECHNOLOGY, LLC (US) 2023-07-06 — — US claimed
CN-116270662-A Moxifloxacin and dexamethasone hydrochloride sodium phosphate eye drops 苏州欧康维视生物科技有限公司 2023-06-23 — — CN claimed
WO-2012095774-A1 SELF ASSEMBLED NANOSTRUCTURED SALIVA SUBSTITUTES INDIAN INSTITUTE OF TECHNOLOGY BOMBAY (IN) 2012-07-19 — — WO claimed
EP-1599190-A2 CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF Glenmark Pharmaceuticals Limited (IN) 2005-11-30 — — EP claimed
US-20040185097-A1 Controlled release modifying complex and pharmaceutical compositions thereof GLENMARK PHARMACEUTICALS LTD. 2004-09-23 — — US claimed
WO-2004066910-A2 CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF GLENMARK PHARMACEUTICALS LTD. (US) 2004-08-12 — — WO claimed
CN-119433062-A Composition for detecting various urinary tract infection pathogens and drug resistance genes, kit and application thereof 圣湘生物科技股份有限公司 2025-02-14 — — CN disclosed
CN-119096973-A Acellular matrix, preparation method thereof and application of acellular matrix in promoting hair growth 上海白衣缘生物工程有限公司 2024-12-10 — — CN disclosed
US-20240358829-A1 Lymphocyte Population and Methods for Producing Same AVM BIOTECHNOLOGY, LLC (US) 2024-10-31 — — US disclosed
US-20240299415-A1 TREATMENT METHOD FOR INTERSTITIAL PNEUMONIA SHENZHEN EVERGREEN THERAPEUTICS CO LTD (CN) 2024-09-12 — — US disclosed
CN-117899082-B Application of sinomenine hydrochloride in preparing medicament for preventing/treating retina diseases 湖南中医药大学 2024-08-27 — — CN disclosed
EP-4395784-A1 LYMPHOCYTE POPULATION AND METHODS FOR PRODUCING SAME AVM Biotechnology, LLC (US) 2024-07-10 — — EP disclosed
CN-118304335-A Method for extracting purslane extract, method for preparing extract carbomer gel and application 澳门科技大学 2024-07-09 — — CN disclosed
WO-2011050206-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS OTONOMY, INC. (US) 2011-04-28 — — WO disclosed
WO-2010068432-A1 BLOCK COPOLYMERS AND USES THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2010-06-17 — — WO disclosed
CN-1709395-A Combined Chinese-western medicine composition for treating chicken respiratory tract disease TAIAN SHANNONGDA PHARMACEUTICA (CN) 2005-12-21 — — CN disclosed
EP-1599190-A2 CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF Glenmark Pharmaceuticals Limited (IN) 2005-11-30 — — EP disclosed
WO-2005003145-A1 SHANZHUYU EXTRACT AND USES THEREOF HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) 2005-01-13 — — WO disclosed
US-20040185097-A1 Controlled release modifying complex and pharmaceutical compositions thereof GLENMARK PHARMACEUTICALS LTD. 2004-09-23 — — US disclosed
WO-2004066910-A2 CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF GLENMARK PHARMACEUTICALS LTD. (US) 2004-08-12 — — WO disclosed
Send feedback